1. Positive effects of low dose IMPX977 on Rett syndrome related MeCP2 targeted-genes
- Author
-
Hui Fu, Si-guang Li, Ke-ping Hu, Ying Zhao, Liang Le, Xue Bai, Yue-qiang Song, Xinsheng Nan, and Li-xin Qi
- Subjects
Pharmacology ,Drug ,media_common.quotation_subject ,Low dose ,RNA ,Rett syndrome ,Biology ,medicine.disease ,030226 pharmacology & pharmacy ,01 natural sciences ,0104 chemical sciences ,MECP2 ,010404 medicinal & biomolecular chemistry ,03 medical and health sciences ,0302 clinical medicine ,Transcription profiling ,Complementary and alternative medicine ,medicine ,Pharmacology (medical) ,KEGG ,Gene ,media_common - Abstract
Objective To investigate the effect of IMPX977 on MeCP2 targeted-genes and the feasibility of IMPX977 acting as a therapeutic candidate drug for Rett syndrome by genomewide transcription profiling. Methods Rats' cortex of control group, IMPX977-treated low-dose group (10 mg/kg), and IMPX977-treated high-dose group (30 mg/kg) were collected and RNA was extracted from the tissues. Then, RNA was subjected to RNA-sequencing. Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) were used in functional enrichment analysis of differentially expressed genes. Results Six MeCP2 targeted-genes were identified in the low/control categories, but not in the high/control categories. Conclusion Low-dose treatment of IMPX977 (10 mg/kg) showed a positive effect on MeCP2 targeted-genes and it may serve as a drug candidate for Rett syndrome therapy with proper dosage.
- Published
- 2019